Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients
Top Cited Papers
Open Access
- 1 September 2007
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 7 (9) , 2106-2113
- https://doi.org/10.1111/j.1600-6143.2007.01910.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The interplay between host and viral factors in shaping the outcome of cytomegalovirus infectionImmunology & Cell Biology, 2006
- Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipientsBone Marrow Transplantation, 2006
- Kinetics of Cytomegalovirus Load Decrease in Solid‐Organ Transplant Recipients after Preemptive Therapy with ValganciclovirThe Journal of Infectious Diseases, 2005
- ValganciclovirDrugs, 2005
- CytomegalovirusAmerican Journal of Transplantation, 2004
- Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral GanciclovirThe Journal of Infectious Diseases, 2003
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002
- A PROSPECTIVE STUDY OF THE NATURAL COURSE OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL ALLOGRAFT RECIPIENTS1Transplantation, 2000
- Cytomegalovirus (CMV) DNA Load Predicts Relapsing CMV Infection after Solid Organ TransplantationThe Journal of Infectious Diseases, 2000
- PREDICTION OF RECURRENT CYTOMEGALOVIRUS DISEASE AFTER TREATMENT WITH GANCICLOVIR IN SOLID-ORGAN TRANSPLANT RECIPIENTSTransplantation, 1993